COMMUNIQUÉS West-GlobeNewswire

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
10/08/2026
Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimab The primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab’s 60 mg with induction, and [...]
BrewDog Claims London's Summer Park Season with ‘Park IPA’
10/08/2026
Punk IPA becomes “Park IPA” throughout August as BrewDog celebrates one of London’s most iconic summer traditions – great beer, great friends and sunny afternoons in the park. ELTON, United Kingdom, Aug. 10, 2026 (GLOBE [...]
Grey Matters Appoints Radiologist Dr. Jayson A. Lord, MD as Medical Director of its First Dedicated PET Neuroimaging Clinic in the U.S.
10/08/2026
VANCOUVER, British Columbia, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “ Company” or “ Grey Matters ”) (CSE: GREY) (FRANKFURT: AGW0) (OTC: AGNPF), a Canadian healthcare company, is pleased to [...]
Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update
10/08/2026
SION-719 Phase 2a proof-of-concept trial did not achieve key activity endpoint of sweat chloride reduction when added to standard of care; Company is not advancing SION-719 as an add-on to standard of care Potential [...]
Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review
10/08/2026
Neurology Review Software Enhancements Included as Part of Industry-Leading Ceribell Point-of-Care Brain Monitoring System SUNNYVALE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” [...]
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
10/08/2026
Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy Phase 2 JADE101 clinical trial in IgA [...]
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film
10/08/2026
Human factors and clinical study results support planned resubmission of Anaphylm™ NDA in the third quarter of 2026 Self-administration pharmacokinetic (PK) results were comparable to clinician-administered PK results [...]
Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights
10/08/2026
TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter Commercial and government payer coverage for TONMYA meaningfully expanded, now reaching approximately 136 million covered [...]
Instinct Bio Announces Strategic Collaboration with PT PARVA CANDELA to Develop Cosmetics Business in Indonesia
10/08/2026
NEW YORK and TOKYO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) ("Instinct Bio" or the "Company") today announced a cooperation agreement with PT PARVA CANDELA ("PARVA [...]
Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
10/08/2026
Total 2Q 2026 net product revenue of $218.4 million, representing 46% year-over-year growth AUVELITY ® 2Q 2026 net product sales of $180.3 million, representing 51% year-over-year growth SUNOSI ® 2Q 2026 net product [...]
ChemoMetec enters collaboration agreement with Roche Diagnostics
10/08/2026
ANNOUNCEMENT NO. 311 After entering a Letter of Intent with Roche Diagnostics in February 2026, aiming to pursue a collaboration with the goal of creating synergies between the parties’ solutions in the field of [...]
Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
10/08/2026
-- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients – -- Phase 2b PLATEAU clinical trial interim analysis and results on track for [...]
Internationally Recognized Johns Hopkins Oncologist Dr. Stephen J. Noga Joins Immunocine as Chief Medical Officer
10/08/2026
Veteran Physician-Scientist and Cellular Therapy Expert to Help Advance the Future of Personalized Cancer Immunotherapy HOUSTON, TX, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Immunocine Cancer Center today announced the [...]
Reacta Healthcare Announces the Appointment of Iedena Lima as Head of Research and Development
10/08/2026
Extensive Pharma and Medtech Sector Experience Strengthens Senior Leadership to Support Growth and Strategic Expansion DEESIDE, United Kingdom, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Reacta Healthcare, a leading developer [...]
Zelluna ASA: New share capital registered
10/08/2026
Oslo, 10 August 2026: Reference is made to the stock exchange announcement published by Zelluna ASA (the "Company") on 4 August 2026 regarding the Board of Directors resolution to issue 446,752 new shares to Inven2 AS [...]
From a Simple Idea to Thousands of Smiles: Teddy Bears On Call Celebrates 10 Years of Comforting Children in Crisis Through Its 3rd Annual Charity Golf Tournament
10/08/2026
STATEN ISLAND, N.Y, USA, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Teddy Bears On Call, Inc. (TBOC), a volunteer 501(c)(3) nonprofit organization dedicated to comforting children receiving emergency medical treatment, will host [...]
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
10/08/2026
Transaction will enhance Oculis’ strategic flexibility and ownership of Privosegtor while driving long-term value creation Transaction consideration includes $3.8 million up-front cash payment at closing and up to 2,050 [...]
Novonesis to acquire remaining share of MicroBioGen to strengthen yeast capabilities
10/08/2026
Novonesis to acquire remaining share of MicroBioGen to strengthen yeast capabilities COPENHAGEN, Denmark, August 10 – Novonesis has signed an agreement with the intent to acquire MicroBioGen, an Australian biotechnology [...]
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
10/08/2026
ZUG, Switzerland and BARCELONA, Spain, August 10, 2026 Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address [...]

Pages